Article and Video CATEGORIES
This work is still early, but it's been interesting to see a lab-based correlate emerge along with with the observation of women, and particularly older women, doing better in lung cancer studies (several prior posts here). Last year, the folks at Cell Therapeutics, Inc., analyzed results from their trials with Xyotax (post here), which demonstrated that their favorable results were seen in younger women. Estrogen may be very relevant to several biological processes related to lung cancer (reviewed in this post), so there is reason to believe that sex differences in lung cancer outcomes are plausible.
Results at ASCO this year were notable for a couple of presentations that noted a correlation of estradiol levels with lung cancer outcomes. Estradiol is the major form of estrogen in humans, the "female" hormone, although levels are present in men as well. The results for women under 60 vs. 60 and older in a couple of xyotax trials were broken down by estradiol levels. Women with lower estradiol levels did better regardless of their age, while those with higher estradiol levels did less well, again regardless of their age:
So age appears to be more of a surrogate for hormonal status than an independent prognostic factor, at least according to an early analysis.
It would be interesting, though, to see if estradiol levels were also prognostic in men, since men also have detectable levels. In fact, that was looked at in the Xyotax trials, and would you believe that the men with lower estradiol levels (below the median) had a significantly longer survival than the men with higher estradiol levels? Here's the figure for the results, among 318 of 583 men on the STELLAR-3 (carbo/taxol vs. carbo/xyotax) or STELLAR-4 trial (gemcitabine or navelbine vs. xyotax) who had serum samples available:
Note: Estradiol levels are measured differently than in the above curve in women, hence the different numbers (scale).
Unlike women on these xyotax trials, men didn't do better with xyotax regardless of their estradiol levels.
There are trials that are just now beginning to look into using anti-estrogen therapies like tamoxifen or faslodex (fulvestrant) in combination with tarceva or other anti-cancer strategies, to see whether they will confer the survival benefit that seems to be present for post-menopausal women to pre-menopausal women, or maybe even men. Right now, we haven't seen the results of these trials, but I'll be watching for more and will keep everyone posted if we learn more.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi Bluebird, Welcome to GRACE. I'm sorry you're going through this scare and hope it's just inflammation or from an infection you didn't know you had.
A CT would be...
Radiation + Brain Operation has just been discarded due to high risk. They will double Tagrisso dosis and then wait to see if it works, then try traditional Chemo. I would...
Hi and welcome to GRACE. I'm sorry to know you are entering a new stage. I'm not about to comment just now but wanted to let you know I see your...
Edit to say, we can't give advice but we can comment with views and facts. :)
My first thought is to ask if she has been seen at a large...
Hi Barbro, Welcome to GRACE. I'm sorry you're worrying about this. We aren't able to give feedback on scan reports. Interpreting scan reports in this setting is not only unethical but...
Hello Linda, my name is Alexandra Beneke, I'm the Outreach Manager for GRACE. Your willingness to share your experiences and knowledge with the cancer community is truly inspiring. Your dedication to...